Ares Allergy Holdings Aktie [WKN DE: A14Z20 / ISIN: GB00BZ21RF93]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ares Allergy Holdings PLC

31.05.19		Stallergenes Greer Will Be at 2019 EAACI Congress and Present the Results of Its Phase III House Dust Mites Tablet Trial (Businesswire)
05.04.19		Recommended Cash Acquisition of Stallergenes Greer plc ("Stallergenes Greer") by Ares Life Sciences I S.à r.l. ("Waypoint") (Businesswire)
20.11.18		Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint (Businesswire)
14.11.18		Stallergenes Greer Announces U.S. FDA Approval of Pediatric Indication Extension for Oralair® Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy (Businesswire)
29.08.18		Stallergenes Greer Delivers Double Digit Growth and Solid Business Performance in the First Half of 2018; Announces Senior Leadership Succession Plan (Businesswire)
07.06.18		Stallergenes Greer Provides Business Update and Refines Its 2018 Financial Outlook (Businesswire)
23.04.18		Notification to Stallergenes Greer Shareholders of Annual General Meeting on 7 June 2018 (Businesswire)
15.03.18		Stallergenes Greer to Report Full Year Financial Results on 22 March 2018 (Businesswire)
16.02.18		Stallergenes Greer Announces Approval in Japan of Pediatric Use for ACTAIR®, Sublingual Immunotherapy Tablet for the Treatment of House Dust Mite Allergy (Businesswire)
25.01.18		Stallergenes Greer Comments on Share Price Movement (Businesswire)
25.10.17		Stallergenes Greer’s 2017 Innovation Day (Businesswire)
25.10.17		Stallergenes Greer Invests in Adeo Health Science, a Research-Driven Food Company with a Novel Approach in Food Allergy (Businesswire)
02.10.17		Stallergenes Greer Acquires Canadian Medic Savoure, Strengthening Presence in North America (Businesswire)
26.09.17		Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline with Acceptance of Regulatory Submission and New Market Approval (Businesswire)
31.08.17		Stallergenes Greer Reports Strong First Half 2017 Results and Narrows 2017 Financial Guidance (Businesswire)
27.07.17		Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy (Businesswire)
19.06.17		Stallergenes Greer plc: First Real-World Evidence Shows Long Term Benefits of Sublingual Immunotherapy to Control Allergic Rhinitis and Potentially Prevent Allergic Asthma (Businesswire)
01.12.16		Stallergenes Greer Secures €50M Revolving Credit Facility (Businesswire)
16.11.16		Stallergenes Greer’s "Meet the Managers” Event Showcases Progress towards Regaining Global Leadership in Its Field (Businesswire)
14.11.16		Stallergenes Greer Announces Collaboration with the Sean N. Parker Center for Allergy and Asthma Research at Stanford University (Businesswire)
07.10.16		Stallergenes Greer plc: Director/PDMR Shareholding (Businesswire)
09.06.16		Stallergenes Greer Announces Results of 2016 Annual General Meeting (Businesswire)
27.05.16		Update on Stallergenes Greer Manufacturing and Distribution Activities (Businesswire)
04.05.16		Stallergenes Greer plc : Notification to Shareholders of Annual General Meeting on 9 June 2016 (Businesswire)
29.04.16		Stallergenes Greer Announces the Publication of Its 2015 Annual Report (Businesswire)
27.04.16		Stallergenes Greer Announces Its 2015 Full Year Results (Businesswire)
27.04.16		Stallergenes Greer Reports Positive Phase II Japanese Cedar Immunotherapy Tablets Results (Businesswire)
11.04.16		Stallergenes Greer PLC: Daniel Smith Appointed Global Head of Information Technology (Businesswire)
05.04.16		Stallergenes Greer Announces the Approval of ACTAIR® in Australia (Businesswire)
11.03.16		Stallergenes Greer PLC: Notifice to Shareholders of Adoption of Financial Reporting Standard ("FRS”) 102 – ‘Reduced Disclosure Framework’ for Parent Entity (Businesswire)
10.03.16		Stallergenes Greer Authorized to Resume Named Patient Products Manufacturing at Its Antony, France Plant (Businesswire)
22.02.16		Stallergenes Greer Announces Its 2016 Financial Calendar (Businesswire)
10.02.16		Stallergenes Greer PLC: Michele Antonelli Appointed President of Stallergenes SAS and Executive Vice President, Head of Europe & Rest of World (Businesswire)
01.02.16		Stallergenes Greer Announces Resumption of Manufacturing at Its Antony, France Plant (Businesswire)
01.02.16		Stallergenes Greer PLC: Tibor Nemes zum Global Head of Technical Operations berufen (Businesswire)
01.02.16		Stallergenes Greer PLC: Tibor Nemes Appointed Global Head of Technical Operations (Businesswire)
07.12.15		Stallergenes Greer PLC: Recall of Allergy Immunotherapy Products (Businesswire)
02.12.15		Stallergenes Greer Announces a Temporary Suspension of Manufacturing at Its Stallergenes Antony Plant (Businesswire)
19.11.15		Stallergenes Greer Announces the Launch of Actair® in Japan (Businesswire)
10.11.15		Stallergenes Greer Appoints Michele Antonelli as Executive Vice President, Head of International Operations (Businesswire)
06.11.15		Stallergenes Greer PLC : Introducing a New Global Allergy Company (Businesswire)
27.10.15		Ares Allergy Holdings plc Becomes Stallergenes Greer plc (Businesswire)
23.10.15		Ares Allergy Holdings plc Updates on the Development of Its House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma (Businesswire)
14.10.15		Ares Allergy Holdings plc to Hold Business Update on 5 November 2015 and Announces Financial Reporting Schedule (Businesswire)
30.09.15		Ares Allergy Holdings plc Publishes Half-Year 2015 Report and Financial Statements (Businesswire)
21.09.15		Ares Allergy Holdings Plc: Notice of Extraordinary General Meeting on 27 October 2015 (Businesswire)

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Ripple steigt deutlich: Neues ATH noch in 2024?

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Diese Aktien empfehlen Experten zu kaufen

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	02.12.2024 22:17
Kaufwert:	EUR
	Hinzufügen Speichern